Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Probutate

FDA-approved product (cream, topical), marketed as Pandel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Probutate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Asthma
  • Atopic eczema
  • Bursitis
  • Cancer
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • Crohn's disease
  • Dermatitis
  • Endocrine system disease
  • Exanthem
  • Eye inflammation
  • Hemorrhoid
  • Herpes Labialis
  • and 19 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, moderately potent (group ii)
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Probutate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Probutate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations

    NCT07112456 · start 2026-09-01

    Registered record
    Registry ID
    NCT07112456
    Conditions
    Asthma Acute; Asthma Attack; Asthma Exacerbations
    Interventions
    Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare; Placebo nebulization (5 mL normal saline) plus standard asthma care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2029-08-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma Acute; Asthma Attack; Asthma Exacerbations
    InterventionNebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare; Placebo nebulization (5 mL normal saline) plus standard asthma care
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    NCT06124157 · start 2025-05-30

    Registered record
    Registry ID
    NCT06124157
    Conditions
    B Acute Lymphoblastic Leukemia
    Interventions
    Biospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Doxorubicin; Echocardiography Test; Imatinib; Leucovorin; Mercaptopurine; Methotrexate; Multigated Acquisition Scan; Pegaspargase; Prednisolone; Prednisone; Radiation Therapy; Thioguanine; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-30
    Completion
    2030-12-01
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Acute Lymphoblastic Leukemia
    InterventionBiospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol +17 more
    PhasePhase 2
    Registry statusRecruiting

  • The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity

    NCT06478667 · start 2024-12-20

    Registered record
    Registry ID
    NCT06478667
    Conditions
    Acute Myocarditis
    Interventions
    levosemindan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-12-20
    Completion
    2025-01-20
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocarditis
    Interventionlevosemindan
    PhasePhase 3
    Registry statusCompleted

  • Early Intravenous Hydrocortisone in Sepsis

    NCT06217939 · start 2024-06-25

    Registered record
    Registry ID
    NCT06217939
    Conditions
    Sepsis Severe; Shock, Septic
    Interventions
    Early hydrocortisone; Normal saline placebo; Open-label hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2024-06-25
    Completion
    2026-04-25
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis Severe; Shock, Septic
    InterventionEarly hydrocortisone; Normal saline placebo; Open-label hydrocortisone
    PhaseNot applicable
    Registry statusTerminated

  • A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    NCT06136650 · start 2023-12-18

    Registered record
    Registry ID
    NCT06136650
    Conditions
    Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
    Interventions
    Opevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone; Abiraterone acetate; Prednisone acetate; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-18
    Completion
    2030-12-02
    Enrolment
    1,314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
    InterventionOpevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone +3 more
    PhasePhase 3
    Registry statusRecruiting

  • Platform of Randomized Adaptive Clinical Trials in Critical Illness

    NCT05440851 · start 2023-04-30

    Registered record
    Registry ID
    NCT05440851
    Conditions
    Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
    Interventions
    Ultra-Protective Ventilation Facilitated by Extracorporeal Support; Lung-Protective Ventilation (LPV); Driving Pressure-Limited Ventilation (DPL); Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS); Early Cohort corticosteroid dose; Extended Cohort corticosteroid dose; Usual care without routine corticosteroids; Usual care without extending corticosteroids; Usual care with fludrocortisone; Usual care without fludrocortisone; Drug 4 mL:; Drug 40 mg:; PEEP-20; PEEP-AOP; PEEP-10; VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation; Electrical impedance tomography (EIT); no treatment / intervention arm is involved; Usual care; Early Routine IMT; no treatment / intervention arm is involved.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-04-30
    Completion
    2027-03-31
    Enrolment
    6,250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
    InterventionUltra-Protective Ventilation Facilitated by Extracorporeal Support; Lung-Protective Ventilation (LPV); Driving Pressure-Limited Ventilation (DPL); Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS) +17 more
    PhaseNot applicable
    Registry statusRecruiting

  • rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers

    NCT04180969 · start 2023-04-10

    Registered record
    Registry ID
    NCT04180969
    Conditions
    Stress; Healthy
    Interventions
    yohimbine + hydrocortisone; medial prefrontal cortex rTMS; Placebo oral tablet; sham rTMS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-04-10
    Completion
    2023-04-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress; Healthy
    Interventionyohimbine + hydrocortisone; medial prefrontal cortex rTMS; Placebo oral tablet; sham rTMS
    PhasePhase 2
    Registry statusWithdrawn

  • Venetoclax Basket Trial for High Risk Hematologic Malignancies

    NCT05292664 · start 2023-03-29

    Registered record
    Registry ID
    NCT05292664
    Conditions
    Myelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Lymphoblastic Lymphoma, in Relapse; Lymphoblastic Lymphoma, Refractory; Acute Leukemia of Ambiguous Lineage in Relapse; Acute Leukemia of Ambiguous Lineage
    Interventions
    Venetoclax; Azacitidine; Cytarabine; Methotrexate; Hydrocortisone; Leucovorin; Dexamethasone; Vincristine; Doxorubicin; Dexrazoxane; Calaspargase Pegol; Erwinia asparaginase
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-03-29
    Completion
    2030-07-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia +7 more
    InterventionVenetoclax; Azacitidine; Cytarabine; Methotrexate +8 more
    PhasePhase 1
    Registry statusRecruiting

  • Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency

    NCT05435781 · start 2022-06-07

    Registered record
    Registry ID
    NCT05435781
    Conditions
    Adrenal Insufficiency; Polymyalgia Rheumatica; Giant Cell Arteritis
    Interventions
    Hydrocortisone; Placebo for hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-06-07
    Completion
    2028-03-01
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenal Insufficiency; Polymyalgia Rheumatica; Giant Cell Arteritis
    InterventionHydrocortisone; Placebo for hydrocortisone
    PhasePhase 4
    Registry statusRecruiting

  • Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors

    NCT04921189 · start 2021-12-31

    Registered record
    Registry ID
    NCT04921189
    Conditions
    Out-Of-Hospital Cardiac Arrest; Postcardiac Arrest Syndrome
    Interventions
    The combined supplement of Ascorbic acid, Thiamine, and Cortisol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-12-31
    Completion
    2025-06-09
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOut-Of-Hospital Cardiac Arrest; Postcardiac Arrest Syndrome
    InterventionThe combined supplement of Ascorbic acid, Thiamine, and Cortisol; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Salivary Cortisol Measurement in Corticotrope Deficiency Substitution With Hydrocortisone.

    NCT05457296 · start 2021-01-01

    Registered record
    Registry ID
    NCT05457296
    Conditions
    Adrenal Insufficiency
    Interventions
    Hydrocortisone (capsule)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2021-04-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenal Insufficiency
    InterventionHydrocortisone (capsule)
    PhasePhase 4
    Registry statusCompleted

  • Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency

    NCT04536662 · start 2020-10-01

    Registered record
    Registry ID
    NCT04536662
    Conditions
    Congenital Adrenal Hyperplasia
    Interventions
    Hydrocortisone; Prednisone; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-10-01
    Completion
    2022-12-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia
    InterventionHydrocortisone; Prednisone; Dexamethasone
    PhasePhase 4
    Registry statusUnknown

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)

    NCT04301479 · start 2020-03

    Registered record
    Registry ID
    NCT04301479
    Conditions
    Vasoplegia; Cardiac Surgery
    Interventions
    hydrocortisone sodium succinate; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-03
    Completion
    2021-03
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasoplegia; Cardiac Surgery
    Interventionhydrocortisone sodium succinate; Saline
    PhasePhase 3
    Registry statusUnknown

  • Steroid-reducing Effects of Crisaborole

    NCT03832010 · start 2019-12-17

    Registered record
    Registry ID
    NCT03832010
    Conditions
    Atopic Dermatitis; Eczema
    Interventions
    Crisaborole; Hydrocortisone Ointment; Triamcinolone ointment; Aquaphor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-12-17
    Completion
    2024-02-16
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis; Eczema
    InterventionCrisaborole; Hydrocortisone Ointment; Triamcinolone ointment; Aquaphor
    PhasePhase 4
    Registry statusCompleted